1. A pharma stock worth keeping an eye is Sun Pharma as it has been showing a cionsistent growth even in times of recession. Moreover when its peers are struggling, it is growing by leaps and bounds. If we study its past ten years behaviour of the stock we will find that it has grown steadily by 28 per cent and has increased the revenues by 33 per cent on an average. One will be impressed with its profit margin which has grown impressively at an average 37 per cent (CAGR) over the period and average profit margins have stayed close to 24 per cent.

2. It has large presence in producing drugs related to lifestyle related diseases. Its main drug to treat diabetes is growing at 16 per cent CAGR and cardiovascular diseases drug is growing at 15 per cent CAGR and this uptrend is likely to continue considering the sedentary life style of the population.

3. Unlike its peers this stock company has been able to maintain its revenue guidance for the current year.